Clinical Trials Logo

Filter by:
NCT ID: NCT03164616 Recruiting - Clinical trials for Non Small Cell Lung Cancer NSCLC

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

POSEIDON
Start date: June 1, 2017
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

NCT ID: NCT03143153 Recruiting - Clinical trials for Various Advanced Cancer

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

CheckMate 648
Start date: June 19, 2017
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin

NCT ID: NCT03138486 Not yet recruiting - Clinical trials for Various Advanced Cancer

A Study of the Effectiveness in Patients With Gastric or Gastroesophageal Junction Cancer With Nivolumab by Itself or in Combination With Ipilimumab and in Patients With Esophageal Cancer With Combination of Nivolumab and Ipilimumab.

CheckMate 648
Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

The main purpose of this study for patients with gastric or gastroesophageal cancer is to evaluate how well the tumor is responding to treatment with nivolumab by itself, or in combination with ipilimumab. For patients with esophageal cancer, the main purpose is to evaluate how well the tumor is responding to treatment with the combination of nivolumab and ipilimumab.

NCT ID: NCT03114657 Recruiting - Alzheimer's Disease Clinical Trials

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

CREAD 2
Start date: March 29, 2017
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

NCT ID: NCT03084081 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

An Innovative Treatment for Cervical Precancer (UH3)

UH3
Start date: July 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this academic-industrial partnership will compare the CryoPen® and thermoablator to traditional CO2-based cryotherapy for the treatment of cervical precancer in low and middle income countries (LMICs) and investigate whether the cure rates of cervical intraepithelial neoplasia 2 and more severe diagnoses (CIN2+) with these devices are non-inferior compared to that of conventional cryotherapy. The results of this study will affect other research areas by serving as a springboard to exploring treatment alternatives that are amenable to low-resource settings and thus will reach the most vulnerable populations.

NCT ID: NCT03078894 Recruiting - Tropical Disease Clinical Trials

A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru

Start date: March 17, 2017
Phase: N/A
Study type: Observational

Tropical diseases are continuously on the rise throughout the world as they are spreading and manifesting in various locations globally. The more prominent vector tends to be the mosquito after it bites a previously infected host. The viruses of Zika, Chikungunya, and Dengue are some of the tropical diseases that are affecting large populations and expanding rapidly. Developing countries are at the highest risk because of the lack of preventive methods that are customarily demonstrated in developed countries. Sanitation issues complicate the problem as contaminated wastewater is ideal for mosquitos to lay eggs. In addition, the organic material in the wastewater serve as food for larvae. The purpose of this study is to test bodies of waters in Peru and examine if contaminated water is a contributing factor in the proportion of the population infected with Zika, Chikanguyna or Dengue.

NCT ID: NCT03074760 Recruiting - Clinical trials for Water-Related Diseases

A Study of Acequias Contamination & Association of Infectious Diseases in Peru

Start date: March 16, 2017
Phase: N/A
Study type: Observational

A major water supply utilized in the Lambayeque region are acequias. Acequias are irrigation canals that are utilized by the agriculture industry for the cultivation of consumables. Utilization of contaminated water to irrigate consumables can lead to foodborne illnesses. Contamination studies on the acequias in the Lambayeque region have not been performed to date. The purpose of this study is to test contamination of acequias in 9 districts in Lambayeque and determine if a difference in infection rates exists in districts with contaminated acequias vs. districts without contaminated acequias for the following diseases: H. pylori, Adenovirus, Rotavirus.

NCT ID: NCT03073109 Recruiting - Clinical trials for Arthritis, Rheumatoid

Patient-Reported Outcomes In Rheumatoid Aarthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions

Start date: March 22, 2017
Phase: N/A
Study type: Observational

This study is aimed to describe the outcomes related to physical activity, activity of disease, quality of life, work productivity and safety in Latin-American patients with Rheumatoid Arthritis (RA) treated with tofacitinib or biological DMARDs after failure to respond to conventional DMARDs in real-life conditions. This will be a non-interventional, hybrid study (prospective and retrospective data collection) comparing tofacitinib to biologic DMARD treatments in patients with RA after failure of conventional DMARDs. The population will be composed by adult patients over 18 years of age diagnosed with RA and who have been prescribed tofacitinib or any biological DMARDs.

NCT ID: NCT03048136 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

CheckMate 955
Start date: March 9, 2018
Phase: Phase 3
Study type: Interventional

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

NCT ID: NCT03043326 Recruiting - HIV Prevention Clinical Trials

Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women

Start date: January 23, 2017
Phase: N/A
Study type: Observational

The purpose of the study is to evaluating the acceptability, use and adherence of a pre-exposure prophylaxis (PrEP) program using the co-formulation tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) administered daily by mouth, at four health facilities and one community-based organization providing health care services for MSM and transgender women. This is an Observational, longitudinal, multicenter, open-label study to evaluate the acceptability, use and adherence to TDF/FTC-based PrEP in volunteer men who have sex with men and transgender women at substantial high risk of acquiring HIV, who were prescribed for PrEP , following the clinical guidelines to prevent HIV infection of the U.S. Centers for Disease Control and Prevention (2014) and the World Health Organization (2015). Follow-up: Participants will be followed for 96 weeks (approximately two years) after the start of prophylactic treatment. Implementation Target Population: Adults (≥18 years of age), without HIV infection diagnosis, and who were prescribed with PrEP and have a substantial risk of acquiring HIV infection according to the international guidelines for HIV prevention. Sample Size: 1,000 participants Implementation Sites: 1. Asociación Civil Impacta Salud y Educación, Barranco study site 2. Asociación Civil Impacta Salud y Educación, San Miguel study site 3. Asociación Civil Selva Amazónica, ACSA study site 4. Asociación Vía Libre, Vía Libre study site 5. Espacio Común, Epicentro study site Primary Objectives: 1. Describing the acceptability and its socio-demographic and sexual behavior correlates for the use of PrEP. 2. Evaluate the persistence of the use of PrEP and its correlates with risk behaviors 3. Evaluating the adherence to the PrEP using self-reporting and pill counts Secondary Objectives: 1. Describing the changes over time in risky sexual behavior among study participants. 2. Describing the number of participants who acquire HIV infection. 3. Evaluate the deviation of the indication of use of PrEP through self- reporting of its sale or sharing with third parties.